Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.61 |
| ▸ | WDR5 | P61964 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.61 |
| ▸ | NPY1R | P25929 | 2/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.61 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.61 |
| ▸ | HTR3A | P46098 | 2/20 | 0.61 |
| ▸ | FASN | P49327 | 2/20 | 0.61 |
| ▸ | SARM1 | Q6SZW1 | 2/20 | 0.61 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | IDE | P14735 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rabeprazole SCHEMBL29360086 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Dexrabeprazole SCHEMBL30945135 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL29374701 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL29833678 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Dexrabeprazole SCHEMBL4946138 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Dexrabeprazole SCHEMBL29493315 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Dexrabeprazole SCHEMBL30019061 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL23336 | 1.00 | KMT2A (0.61) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL5945508 | 0.99 | KMT2A (0.60) | KMT2ACYP2C9WDR5LMNAENGASE | |
| Rabeprazole SCHEMBL491362 | 0.99 | KMT2A (0.60) | KMT2ACYP2C9WDR5LMNAENGASE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15181 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107208-A1 | COMPOSITIONS AND METHODS FOR TREATING MICROBIAL INFECTIONS | THE METHODIST HOSPITAL (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4735895-A1 | HELICOBACTER CAGA PEPTIDES AND THEIR USE IN DIAGNOSIS | Biotome Pty Ltd (AU) | 2026-05-06 | — | — | EP | claimed |
| WO-2026090593-A2 | RNA BIOMARKERS FOR USE IN BARRETT'S ESOPHAGUS | CITY OF HOPE (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731180-A1 | A POWDER COMPOSITION FOR ORAL SUSPENSION OF PROTON PUMP INHIBITORS AND THE METHOD OF PREPARING THE SAME | Orbit Pharma Limited (GB) | 2026-04-29 | — | — | EP | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-20260097026-A1 | INHIBITION OF AORTIC VALVE CALCIFICATION | ZABIRNYK ARSENII (NO) | 2026-04-09 | — | — | US | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-4719351-A2 | MARIBAVIR COMPOSITIONS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2026-04-08 | — | — | EP | claimed |
| US-20260091116-A1 | COMPOSITIONS AND KITS FOR OMEPRAZOLE SUSPENSION | AZURITY PHARMACEUTICALS, INC. | 2026-04-02 | — | — | US | claimed |
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| WO-1999044595-A2 | PHARMACEUTICAL COMPOSITIONS FOR ULCER | NICOX S.A. (FR) | 1999-09-10 | — | — | WO | claimed |
| WO-1999045004-A1 | NITRATE SALT OF ANTI-ULCER MEDICINE | NICOX S.A. (FR) | 1999-09-10 | — | — | WO | claimed |
| WO-1999030693-A2 | A DOUBLE CAPSULE FOR THE ADMINISTRATION OF ACTIVE PRINCIPLES IN MULTIPLE THERAPIES | AXCAN PHARMA INC. (CA) | 1999-06-24 | — | — | WO | claimed |
| WO-1999029299-A1 | NOVEL SUPPOSITORY FORM COMPRISING AN ACID-LABILE ACTIVE COMPOUND | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-06-17 | — | — | WO | claimed |
| WO-1999029320-A1 | NOVEL ADMINISTRATION FORM COMPRISING AN ACID-LABILE ACTIVE COMPOUND | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-06-17 | — | — | WO | claimed |
| WO-1999010000-A1 | COMBINED PREPARATIONS FOR TREATING UPPER GASTROINTESTINAL TRACT DISTRESS | THE PROCTER & GAMBLE COMPANY (US) | 1999-03-04 | — | — | WO | claimed |
| WO-1999004816-A1 | PROTON PUMP INHIBITOR IN THERAPEUTIC COMBINATION WITH ANTIBACTERIAL SUBSTANCES | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1999-02-04 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| US-5700410-A | Method of manufacturing wax matrices | NIPPON SHINYAKU CO., LTD. (JP) | 1997-12-23 | — | — | US | claimed |
| EP-0580860-B1 | METHOD OF MANUFACTURING SOLID DISPERSION | NIPPON SHINYAKU CO LTD (JP) | 1997-10-22 | — | — | EP | claimed |